SCM
BDTX icon

Soleus Capital Management’s Black Diamond Therapeutics BDTX Stock Holding History

Soleus Capital Management’s Portfolio BDTX Stock Details BDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-435,000
Closed -$2.2M – 97
2023
Q2 		$2.2M Buy
+435,000
New +$888K 0.24% 72

Other funds holding BDTX

BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Soleus Capital Management's BDTX Position: Q3 2023 in Review

Soleus Capital Management sold out of Black Diamond Therapeutics (BDTX) in Q3 2023, closing a stake of 435,000 shares — an estimated $2.2M sold.

Soleus Capital Management first reported a position in BDTX in Q2 2023 and held it in 1 quarter. The position peaked at $2.2M in Q2 2023. 73 funds tracked by Wall St. Rank hold BDTX as of Q3 2023.

  • Soleus Capital Management reported no remaining Black Diamond Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Soleus Capital Management sold 435,000 Black Diamond Therapeutics shares in Q3 2023, an estimated $2.2M.
  • Soleus Capital Management first reported a position in Black Diamond Therapeutics in Q2 2023 and held it in 1 quarter.
  • Soleus Capital Management's Black Diamond Therapeutics position peaked at $2.2M in Q2 2023.
  • 73 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q3 2023.

Based on Soleus Capital Management's 13F filing for Q3 2023, filed 14 Nov 2023.